Galmed Pharmaceuticals (GLMD) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Galmed Pharmaceuticals Ltd. reports a net loss of $2.394 million for the first half of 2024, with research and development, as well as general and administrative expenses as major contributors to the loss. The company’s total assets have decreased to $13.341 million as of June 30, 2024, from $16.629 million at the end of the previous year. This financial update is critical for investors as it may influence the company’s stock valuation and future investment decisions.
For further insights into GLMD stock, check out TipRanks’ Stock Analysis page.